ESPR · Categories · Upgrades
ESPR - Analyst upgrades
Esperion Therapeutics Inc. (ESPR) analyst upgrades - real-time wire coverage filtered to Upgrades only.
Recent Upgrades for ESPR
- Esperion Therapeutics upgraded by Northland CapitalNorthland Capital upgraded Esperion Therapeutics from Under Perform to Market Perform
- Esperion Therapeutics upgraded by BofA Securities with a new price targetBofA Securities upgraded Esperion Therapeutics from Underperform to Buy and set a new price target of $4.00 from $1.25 previously
- Esperion Therapeutics upgraded by Credit Suisse with a new price targetCredit Suisse upgraded Esperion Therapeutics from Underperform to Neutral and set a new price target of $7.00 from $6.50 previously
- Esperion Therapeutics upgraded by Jefferies with a new price targetJefferies upgraded Esperion Therapeutics from Hold to Buy and set a new price target of $12.00
- Esperion Therapeutics upgraded by Morgan Stanley with a new price targetMorgan Stanley upgraded Esperion Therapeutics from Underweight to Equal-Weight and set a new price target of $9.00
- Esperion Therapeutics upgraded by JP Morgan with a new price targetJP Morgan upgraded Esperion Therapeutics from Underweight to Neutral and set a new price target of $6.00